CytoMed Therapeutics Ltd. Expands into Auto-Immune Disease Treatments Following Strategic Cord Blood Bank Acquisition
I'm PortAI, I can summarize articles.
CytoMed Therapeutics Ltd. has expanded into autoimmune disease treatments following its acquisition of a cord blood bank. The company will scale natural killer (NK) cells from cryopreserved cord blood, establishing a new business platform for revenue growth. LongevityBank Pte Ltd will focus on autologous therapies, while CytoMed continues developing donor blood-derived therapies. This strategic move may lead to LongevityBank becoming an independent entity, enhancing revenue through Asia's cost-effective R&D and manufacturing capabilities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments